Market Place
Sourcing Support
CARsgen® U.S. Clinical Holds Lifted by FDA
31 Oct 2024 //
PR NEWSWIRE
CARsgen Warning Letter Notes Company Paused Manufacture Following 483
30 Aug 2024 //
FDANEWS
CARsgen® Announces 2024 Interim Results
29 Aug 2024 //
PR NEWSWIRE
CARsgen Therapeutics Receives FDA Warning Letter
27 Aug 2024 //
FDA
CARsgen Presents First-in-human Results of GPRC5D CAR-T CT071 at EHA 2024
15 Jun 2024 //
PR NEWSWIRE
CARsgen Presents Updated Results on Satri-cel in Nature Medicine at 2024 ASCO
05 Jun 2024 //
PRESS RELEASE
CARsgen: Satri-cel Updates In Nature Medicine & At ASCO 2024
04 Jun 2024 //
PR NEWSWIRE
CARsgen Announced 2023 Annual Results
27 Mar 2024 //
PR NEWSWIRE
NMPA Approves the NDA for CARsgen`s BCMA CAR-T Therapy Zevorcabtagene Autoleucel
01 Mar 2024 //
PR NEWSWIRE
CARsgen`s Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting
19 Jan 2024 //
PR NEWSWIRE
CARsgen`s CT011 achieves IND clearance from the NMPA
15 Jan 2024 //
PR NEWSWIRE
FDA puts 3 CARsgen CAR-Ts on hold after inspecting facility
14 Dec 2023 //
FIERCE BIOTECH
CARsgen Presents Research Results on Zevor-cel at 2023 ASH Annual Meeting
12 Dec 2023 //
PR NEWSWIRE
CARsgen`s CT071 Received IND Clearance from the FDA
04 Dec 2023 //
PR NEWSWIRE
CARsgen`s CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma
12 Oct 2023 //
PR NEWSWIRE
Two Cases of Pancreatic Cancer Treatment with CARsgen`s CT041 Published
21 Sep 2023 //
PR NEWSWIRE
CARsgen Announced 2023 Interim Results
22 Aug 2023 //
PR NEWSWIRE
Moderna and CARsgen team up on CAR-T cell therapy and mRNA cancer vaccine combo
22 Aug 2023 //
ENDPTS
CARsgen begins trial of CAR T-cell therapy for gastric cancer
19 May 2023 //
CLINICAL TRIALS ARENA
CARsgen Initiates Phase 2 Clinical Trial for CT041 in the U.S.
18 May 2023 //
PR NEWSWIRE
CARsgen`s CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA
05 May 2023 //
PR NEWSWIRE
CARsgen`s CAR T-cell Candidate CT041 Achieves IND Clearance from the NMPA
20 Apr 2023 //
PR NEWSWIRE
CARsgen Announced 2022 Annual Results and Business Updates
22 Mar 2023 //
PR NEWSWIRE
CARsgen Announces Agreement to Evaluate AB011 with PD-L1 to Treat Gastric Cancer
01 Feb 2023 //
PR NEWSWIRE
CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI
20 Jan 2023 //
PR NEWSWIRE
CARsgen, Huadong Medicine ink deal to sell CAR T-cell product in China
17 Jan 2023 //
PR NEWSWIRE
CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel
12 Dec 2022 //
PRNEWSWIRE
CARsgen Appoints Sylvie Peltier as SVP of Global Regulatory Affairs
31 Oct 2022 //
PRNEWSWIRE
CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA
18 Oct 2022 //
PRNEWSWIRE
CARsgen Presents North America Phase 2 Updates for CT053 BCMA CAR T
21 Sep 2022 //
BUSINESSWIRE
CARsgen Releases the First Clinical Batch of CAR T Cells
02 Sep 2022 //
BUSINESSWIRE
CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Pipeline
24 Aug 2022 //
PRNEWSWIRE
Case Report of CRL in Hepatocellular Carcinoma to CARsgen`s CT011
18 Aug 2022 //
PRNEWSWIRE
CARsgen Appoints Dr. Hua Jiang as Executive Director
02 Aug 2022 //
PRNEWSWIRE
CARsgen Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors
06 Jun 2022 //
PRNEWSWIRE
Nature Medicine Publishes from CARsgen`s CT041 Claudin18.2 CAR T Cells Trial
10 May 2022 //
PRNEWSWIRE
CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer
07 Apr 2022 //
PRNEWSWIRE
CARsgen Completes cGMP Commercial Manufacturing Facility
10 Mar 2022 //
CONTRACTPHARMA
CARsgen & CRB to Celebrate Completion of cGMP Commercial Manufacturing Facility
21 Feb 2022 //
PRNEWSWIRE
CARsgen Appoints Richard John Daly as the President
17 Jan 2022 //
PRNEWSWIRE
FDA Grants RMAT Designation to CARsgen`s CT041 CAR T-cell Product Candidate
10 Jan 2022 //
PRNEWSWIRE
CARsgen Presents Updated Research Results on CT053 at ASH 2021
11 Dec 2021 //
PRNEWSWIRE
CARsgen Announces CAR T-cell Product Candidate CT041 by the EMA
15 Nov 2021 //
WFMZ
CARsgen Announces CT041 Granted PRIME Eligibility by the EMA
15 Nov 2021 //
BIOSPACE
Appealing Data of CARsgen`s CAR-T in Advanced Gastric Cancer Presented at ESMO
19 Sep 2021 //
PRNEWSWIRE
CARsgen Therapeutics officially listing on HKEX
18 Jun 2021 //
PRNEWSWIRE
CARsgen Therapeutics Receives Orphan Medicinal Product Designation from the EMA
01 Mar 2021 //
PRNEWSWIRE
CARsgen Receives Orphan Medicinal Product Designation from the EMA
01 Mar 2021 //
PRNASIA
CARsgen Presents Updated Multiple Myeloma Cell Therapy Data at the 62nd (ASH)
05 Dec 2020 //
PRNEWSWIRE
CARsgen to Present Multiple Myeloma Cell Therapy Dat
20 Nov 2020 //
PRNNEWSWIRE
USFDA grants orphan drug designation to CARsgen Therapeutics
06 Oct 2020 //
BIOSPECTRUMASIA
USFDA grants orphan drug designation to CARsgen Therapeutics
05 Oct 2020 //
BIOSPECTRUMASIA
US FDA grants orphan drug designation to CARsgen’s CT041 CLDN18.2 CAR-T cells
05 Oct 2020 //
PHARMABIZ
CARsgen Therapeutics Receives IND Clearance from the NMPA for CT041 CLDN18.2
20 Aug 2020 //
PRNASIA
CARsgen Announces the Pub of a Novel CAR-T Technology that Improves the Efficacy
17 Aug 2020 //
PRNEWSWIRE
CARsgen Announces the Pub of a Novel CAR-T Technology that Improves the Efficacy
17 Aug 2020 //
PRNASIA
US FDA clears CARsgen Therapeutics’ IND for CT041 CLDN18.2-CAR-T cells
19 May 2020 //
PHARMABIZ
CARsgen Therapeutics Receives IND Clearance from the US FDA for CT041 CLDN18
18 May 2020 //
PRNEWSWIRE
CARsgen Therapeutics Receives Positive EMA Opinion on ODD s (CT053)
27 Apr 2020 //
PR NEWSWIRE
CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation
27 Apr 2020 //
PR NEWSWIRE
